FREMONT, Calif. , Sept. 13, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) requesting U.S. marketing authorization of tenapanor for the treatment of patients with irritable bowel

FREMONT, Calif. , Aug. 29, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the peer-reviewed journal Science Translational Medicine .

Operating Runway Extended to Mid-2020 Preparing to Submit NDA for Tenapanor in IBS-C in Early Q4 2018 Conference Call to be Held Today at 4:30 p.m. ET FREMONT, Calif. , Aug. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the second

FREMONT, Calif. , Aug. 1, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018 . Management will host a conference call and webcast that afternoon at 4:30 p.m.

FREMONT, Calif. , May 29, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present a company overview at the Jefferies Global Healthcare Conference on Tuesday, June 5, 2018 at 2:30 p.m. ET in New York City .

FREMONT, Calif. , May 22, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $4.00 per share, before underwriting discounts and commissions, for gross proceeds of

FREMONT, Calif. , May 21, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced it has entered into a $50.0 million senior secured term loan facility with Solar Capital Ltd. and the Life Sciences Group at Bridge Bank , a division of Western Alliance Bank .

FREMONT, Calif. , May 21, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that it has commenced an underwritten public offering of up to $50,000,000 of shares of its common stock. All of the shares to be sold in the offering will be offered by Ardelyx .

On Track to Submit NDA for Tenapanor in IBS-C in Second Half of 2018 Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia FREMONT, Calif. , May 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the first

License Agreement Advances First-in-Class Tenapanor for IBS-C and Hyperphosphatemia in Canada Ardelyx to Receive Up to CAD 25 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif. , March 19, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced a license agreement with